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COMMENT
Clinical exome sequencing in daily practice: 1,000
patients and beyond
Wendy A van Zelst-Stams, Hans Scheffer and Joris A Veltman*
Diagnostic exome sequencing
Using next-generation sequencing technology to se-
quence the coding regions of all human genes, known as
exome sequencing, has rapidly become one of the most
successful methods for genetic disease research since its
introduction in 2009 [1]. The possibility to investigate all
genes for mutations in a single experiment holds great
promise in the diagnostic arena, in particular for genet-
ically heterogeneous disorders and clinically undiag-
nosed diseases. Laboratories, including our own, have
now started to offer exome sequencing as a diagnostic
test. In this article, we share our experience with diag-
nostic exome sequencing and discuss the impact of these
novel diagnostic methods on medical practice, now and
in the future.
What have we learned so far?
We set up exome sequencing in our diagnostic labora-
tory, which is quality accredited in compliance with
International Organization for Standardization (ISO)
standard 15189 (similar to Clinical Laboratory Improve-
ment Amendments accreditation), and patient inclusion
and counseling were coordinated by our clinical genetics
unit, both located within the Department of Human
Genetics of the Radboud University Medical Center. We
immediately noted a high demand from referring clini-
cians for exome sequencing because of the number of
unsolved genetic diseases. We initially had to restrict pa-
tient inclusion because of limited sequencing capacity
and high costs; we also wanted to build up experience in
clinical interpretation. Inclusion was also restricted to
referral by in-house clinical geneticists so that adequate
genetic counseling could be provided to patients before
and after this novel test was performed, as well as allow-
ing us to learn from unexpected findings and easily
adapt procedures.
We encountered no major hurdles while setting up the
highly automated exome sequencing in the laboratory,
making use of our unit’s extensive experience with this
approach. More than 1,000 diagnostic exomes have been
sequenced so far in our department, and we are now
scaling up this approach to many more genetic diseases
in collaboration with our partners at BGI Europe. Much
of the workload in exome sequencing has shifted from
the wet laboratory to the dry laboratory, specifically the
data analysis and subsequent interpretation and report-
ing. This requires a dedicated team of computational
scientists working together with clinical laboratory
geneticists and clinical geneticists. Interpretation of the
pathogenicity of variants is greatly facilitated by the rap-
idly expanding reference databases of genetic variation,
such as the National Center for Biotechnology Informa-
tion Single Nucleotide Polymorphism Database and the
National Heart, Lung, and Blood Institute exome variant
server. However, such interpretation requires expert
knowledge and careful use of these normal variation fre-
quencies in combination with pathogenicity prediction
tools and other useful annotations.
One of the main issues we found in counseling pa-
tients prior to exome sequencing involved the potential
identification of unsolicited, incidental or secondary
findings - genetic variants that are medically relevant
but not for the disease for which the patients visited the
clinic [2]. It was unclear at the start of this endeavor
how frequently such a variant would be found during
the diagnostic process, and what kind of variants would
be observed. Our previous experience with non-targeted
diagnostic approaches was limited to genome-wide
array-based diagnostics and classical cytogenetics. Many
clinicians feared that the number of unsolicited findings
would be very high and do more harm than good to the
patients, and complicate diagnostic procedures. We
therefore decided from the start to establish an inde-
pendent expert panel that could determine the clinical
relevance of such unsolicited findings, to counsel all pa-
tients and families involved about the possibility of
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unsolicited findings and consent them to being informed
if the expert panel determined the findings clinically
relevant, and to restrict diagnostic interpretation as
much as possible to mutations in known disease-causing
genes.
A list of known disease-causing genes was made for
each condition tested by exome sequencing. Variants
outside these genes were automatically filtered out dur-
ing the data analysis. This minimized the risk of unsoli-
cited findings and at the same time selected for exome
variation that was most likely to explain a particular
disease, an approach that we have used successfully for
disorders like blindness, deafness, movement disorders,
hereditary cancer and mitochondrial disorders. For most
of the disorders studied, with the exception of microsat-
ellite stable colorectal cancer, the diagnostic yield of
exome sequencing was clearly superior to that of trad-
itional sequential gene testing, reaching up to 52% for
patients with blindness [3]. Importantly, we learned that
the phenotypic definition of a disease and associated
gene list should not be too restricted, as disease genes
may have a much broader phenotypic spectrum than
previously reported.
For intellectual disability, which mostly occurs sporad-
ically and for which the majority of disease genes are
presently unknown, we took a different strategy. We
focused on de novo mutations as well as recessive muta-
tions occurring throughout the exome, using a patient-
parent trio sequencing approach [4]. This has resulted in a
diagnostic yield of at least 16% in this well-studied patient
group, with an additional 22% of patients harboring
mutations predicted to be pathogenic in strong candidate
genes [5]. This approach obviously does not restrict the
analysis to genes already implicated in a particular clinical
entity. It therefore also leads to a higher chance of identi-
fying unsolicited variants such as de novo mutations in
cancer predisposition genes. In our first series of 100
patients, we identified a de novo mutation in RB1, associ-
ated with retinoblastoma, in a patient with severe intellec-
tual disability. The expert panel considered the risk of
retinoblastoma to be negligible for this patient, given that
he had reached the age of 8 years with no tumor occur-
rence, but decided that it was important to inform the
parents of the small chance that a sudden, painful swelling
of the limbs could be caused by an osteosarcoma and that
they should consult an oncologist at the first sign of such
swelling.
International discussion on the reporting of unsolicited
findings has, meanwhile, intensified. The American Col-
lege of Medical Genetics, among others, recommends
that a limited number of medically relevant variants
should be specifically sought and reported in each pa-
tient undergoing exome or genome sequencing [6]. We
are actively involved in these discussions and agree with
recent recommendations by the European Society of
Human Genetics that unsolicited genetic variants indica-
tive of treatable or preventable health problems should
be reported [7].
One of the major remaining issues is now to reduce
the turnaround time from months to weeks, so referring
clinicians can rely on exome sequencing as a rapid and
robust diagnostic approach. This is now a realistic possi-
bility because of the increased speed, throughput and
quality of the latest next-generation sequencing plat-
forms, in combination with faster data-analysis pipelines.
Still, it is important to note here that current exome
sequencing is far from perfect and should be further
improved [8]. Many exons are not enriched and/or
sequenced well, insertion-deletions as well as structural
variation are only partially detected and homologous
sequences cause problems in the correct mapping of
sequencing reads. It is therefore clear that, at present, it
is not the best test available to exclude pathogenic muta-
tions in a specific gene or set of genes. If this is required,
we currently recommend deep sequencing of relevant
gene panels. In addition, exome sequencing is not the
preferred method for the detection of other mutational
mechanisms such as trinucleotide expansions or imprint-
ing defects. Finally, Sanger sequencing validation of all
clinically relevant variants is still highly recommended at
this time.
Impact of exome and genome sequencing on
medical practice
Although technological improvements are essential for
the widespread clinical implementation of exome se-
quencing, we have no doubt that these will be developed
in the coming years. It will not be long before exome
and, not much later, genome sequencing become stand-
ard tools in each genetic laboratory. We anticipate that
it will not be too much longer before exome or genome
data are available to a clinician within hours to minutes,
and therefore can be used during the first clinical evalu-
ation of a patient. This rapid availability of genomic
information is crucial for genetics to play a more central
role in modern medicine, as time is of primary import-
ance in clinical decision-making. An example of this was
recently given for applications of rapid whole-genome
sequencing to diagnose rare genetic diseases in neonatal
intensive care units [9].
Affordable and rapid availability of exome or genome
information will also have a major impact on the role of
both the clinical geneticist and the laboratory specialist.
Traditionally, an important role of the clinical geneticist
was to request the best genetic test for confirmation of a
clinical diagnosis at the molecular level. This request
was based on expert knowledge in clinical phenotyping
of mostly rare genetic diseases after other medical
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specialists had excluded more common causes. The la-
boratory specialist would perform these tests and inter-
pret the data. However, in the near future, the clinical
geneticist will be involved in the first clinical examin-
ation of a patient in the case of many diseases as an ex-
pert who can rapidly link a patient’s phenotype with his
or her genotype, both of which are in front of the clin-
ician. The laboratory specialist will support the clinical
geneticist in this process, and perform additional tests to
confirm pathogenicity of individual genomic variants or
study more complex modes of inheritance. Increasingly,
genetics will be used to determine the right therapy and
for monitoring treatment efficacy. This futuristic sce-
nario is closer than many of us may think, and will re-
quire a change in our laboratory and clinical training
programs and a further integration of genetics in the
clinic. A first important step towards these goals is the
implementation of exome sequencing as a first-tier test
for genetically heterogeneous disorders.
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